Cancer combo trial halted before full results

NCT ID NCT04284488

Terminated Disease control Sponsor: Ascentage Pharma Group Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the study was terminated early, so we have limited information on how well it worked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APG-1387 and toripalimab (a type of immunotherapy)
What this could lead to: If it had succeeded, this combination might have offered a new treatment option for certain advanced cancers that are hard to treat.
What could go wrong: The trial was terminated early, so results are limited. The study was small and early-stage, meaning even if it worked, it would need much more testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer nasopharyngeal carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Foshan First People's Hospital

Foshan, Guangdong, China
Sun-Yat Sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The Affiliated Hospital OF Guangxi Medical University

Nanning, Guangxi, 530021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.